Novartis AG
NVS
$164.70
$2.031.25%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.67% | -2.80% | 12.06% | 27.96% | -11.63% |
| Total Depreciation and Amortization | -6.67% | 8.53% | 0.87% | -1.29% | 0.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 200.63% | -75.38% | 45.41% | 92.26% | -58.15% |
| Change in Net Operating Assets | -314.47% | 552.76% | 108.13% | -686.27% | -130.95% |
| Cash from Operations | -65.55% | -1.40% | 82.83% | -13.07% | -33.30% |
| Capital Expenditure | -72.03% | -6.95% | -30.31% | 54.48% | -73.83% |
| Sale of Property, Plant, and Equipment | 0.00% | 0.00% | -90.00% | -78.72% | 4,600.00% |
| Cash Acquisitions | -1,146.24% | 94.41% | -- | -- | -634.48% |
| Divestitures | 85.94% | -481.82% | -175.00% | -102.44% | 2,242.86% |
| Other Investing Activities | 6.29% | -47.06% | -141.18% | 125.58% | -75,233.33% |
| Cash from Investing | -144.65% | 61.66% | -779.70% | 110.88% | -710.96% |
| Total Debt Issued | 3,697.04% | -84.12% | 52.88% | 2,416.67% | -100.65% |
| Total Debt Repaid | -185.29% | 3.44% | 38.00% | -1,215.85% | 92.93% |
| Issuance of Common Stock | 100.00% | -90.00% | 1,900.00% | -- | -100.00% |
| Repurchase of Common Stock | 35.71% | 15.18% | 0.07% | 1.67% | 3.22% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 53.40% | -- | -- |
| Other Financing Activities | -663.64% | 110.23% | -1,034.78% | 117.97% | -197.67% |
| Cash from Financing | 160.34% | 46.50% | 39.01% | -185.31% | -684.29% |
| Foreign Exchange rate Adjustments | 263.64% | -105.76% | 112.22% | 157.32% | -278.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.21% | 807.32% | 90.67% | -104.33% | -137.68% |